Belgium
News Category
VolitionRx Highlights Growing Clinical Evidence Supporting Nu.Q NETs Test for Sepsis and NETosis-Related Diseases
VolitionRx announces that multiple peer-reviewed studies support its Nu.Q H3.1 test as a biomarker for sepsis, capable of distinguishing it from non-i...
Bill Humphreys Releases 'What If?', a Memoir of Daring Choices and Resilience
Bill Humphreys' new book 'What If?' recounts his extraordinary journey from truck driver to international cyclist and coach, offering lessons on risk-...
VolitionRx Collaborates with Sysmex to Advance Nu.Q® NETs Assay Development
VolitionRx announced a collaboration with Sysmex to optimize its Nu.Q® NETs H3.1 assay on Sysmex's diagnostic platform, targeting a $3.8 billion marke...
VolitionRx Expands Patent Portfolio with Ebola Triage Application
VolitionRx Ltd. has filed a strategic patent application for using its Nu.Q technology to triage and monitor suspected Ebola patients, potentially pro...
VolitionRx Reports Clinical and Commercial Progress Across Diagnostics Portfolio, Including Milestone Payment and Licensing Momentum
VolitionRx provided an update on its diagnostic pipeline, highlighting a feline lymphoma manuscript submission tied to a $5 million milestone payment,...
VolitionRx Reports High Accuracy in Feline Cancer Blood Test Study
VolitionRx announced that its Nu.Q Vet Feline prototype assay demonstrated 97% specificity and identified 86% of lymphoma cases in cats, advancing a b...
European Banks Integrate Crypto into Core Infrastructure, Signaling Industry Shift
KBC's launch of Ether and Bitcoin access through its existing retail framework in Belgium marks a significant shift in how traditional banks adopt dig...
JD.com Expands Joybuy Platform Across Europe, Intensifying Global E-Commerce Competition
JD.com, one of China's largest online retailers, is expanding its Joybuy platform into several European countries, including the UK, Germany, and Fran...
VolitionRx Achieves Over 99% Purity in Circulating Tumor DNA Isolation, Advancing Liquid Biopsy Technology
VolitionRx's Capture-Seq platform achieves over 99% purity in isolating circulating tumor-derived DNA, addressing a key challenge in liquid biopsy and...
VolitionRx Reports Clinical and Commercial Progress Across Multiple Platforms, Including TAM of $23 Billion for New Cancer Detection Method
VolitionRx provided an update on its multi-pillar strategy, highlighting a new cancer detection method with a $23 billion addressable market, progress...